¼ÓÈëVIP ÉÏ´«¿¼²©×ÊÁÏ ÄúµÄÁ÷Á¿ Ôö¼ÓÁ÷Á¿ ¿¼²©±¨°à ÿÈÕÇ©µ½
   
Ö÷Ìâ : µÚËľüÒ½´óѧһ¾Å¾Å¶þÄê¹¥¶Á²©Ê¿Ñ§Î»Ñо¿ÉúÈëѧÊÔÌâ
¼¶±ð: ³õ¼¶²©ÓÑ
ÏÔʾÓû§ÐÅÏ¢ 
Â¥Ö÷  ·¢±íÓÚ: 2007-04-19   

µÚËľüÒ½´óѧһ¾Å¾Å¶þÄê¹¥¶Á²©Ê¿Ñ§Î»Ñо¿ÉúÈëѧÊÔÌâ

µÚËľüÒ½´óѧһ¾Å¾Å¶þÄê¹¥¶Á²©Ê¿Ñ§Î»Ñо¿ÉúÈëѧÊÔÌâ ѧ¿Æ×¨Òµ£º Lljn\5!r<  
^b8~X [1J_  
´«È¾²¡Ñ§ ¿¼ÊÔ¿ÆÄ¿: ÃâÒßѧ p+d-7'?I  
DR#" 3  
Ò». Ãû´Ê½âÊÍ(ÿÌâ4·Ö,¹²32·Ö) 28MMH Q  
^m>4<~/  
1. ICAM-1 B8@mL-Z-;  
y'R}  
2. interleukin 12(IL-12) UC!mp?   
ai !u+L  
3. tumor infiltrating lymphocyte mQ[$U  
/3b *dsYsl  
4. TCR/CD3 complex 2b"*~O;  
) c@gRb~  
5. hematopoietin receptor family c./\sN@  
;blL\|ch;  
6. individual idiotype(IdI) Z\!,f.>g  
,.,8-In^  
7. integrin h@,ja  
(v]%kXy/G  
8. colony-stimulatory factor (CSF) 3[m~-8  
`+H=3`}X  
¶þ. ¼ò´ðÌ⣨ÿÌâ8·Ö£¬¹²32·Ö£© ",#.?vT`  
@Z5q2Q  
1. ÃâÒßÇòµ°°×ÖØÁ´µÄ»ùÒòÈçºÎ½øÐÐÀà±ðת»»(class switching )? MB]E[&Q!  
'xW= qboOp  
2. ¼òÊöɱÉËÐÔTϸ°û(Tc)ɱÉ˲¡¶¾¸ÐȾ°Ðϸ°ûµÄ»úÀí¡£ (.J/Ql0Y  
\/ bd  
3. ÉúÎïÓ¦´ðµ÷½Ú¼Á( biological response modifier,BRM)Ö÷ÒªÓÐÄļ¸Àà?¼òÒª½éÉÜÔÚ´«È¾ÐÔ¼²²¡·ÀÖÎÖеÄ×÷Óᣠ]N>ZOV,>  
eg[EFI.h  
4. ¼òÊö¿¹Ô­Ìá³Êϸ°û(APC)Ó븨ÖúÐÔTϸ°û(Th)Ï໥×÷ÓõĹØÏµ¡£ >AJ/!{jD*  
bt}8ymcG  
Èý. ÎÊ´ðÌâ(ÿÌâ18·Ö,¹²36·Ö) 4I4m4^  
I%T+H[,  
1. ÊÔÊö¸ÉÈÅËØµÄ·ÖÀ༰ÆäÉúÎïѧ×÷ÓÃÌØµã¡£Ö÷Òª¿ÉÒÔÖÎÁÆÄÄЩ´«È¾ÐÔ¼²²¡?¼òÊö¸ÉÈÅËØ¼ì²âµÄ·½·¨ºÍÔ­Àí¡£ !3b& S 4  
6)INr,d  
2. ºÎΪ»ùÒò¹¤³Ì¿¹Ìå?Ŀǰ¹úÄÚÍâÔÚ»ùÒò¹¤³Ì¿¹ÌåÑо¿ÖÐÓÐÄÄЩÖ÷Òª½øÕ¹? µÚËľüÒ½´óѧһ¾Å¾ÅÈýÄê¹¥¶Á²©Ê¿Ñ§Î»Èëѧ¿¼ÊÔÊÔÌâ ѧ¿Æ×¨Òµ: ´«È¾²¡Ñ§¡¢ Ïû»¯ÄÚ¿Æ ¿¼ÊÔ¿ÆÄ¿: ÃâÒßѧ Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© 1. CD4 2. T cell receptor(TCR) o}N@Q-i gq  
L 8 P0bNi  
3. immunoglobulin superfamily (IgSF) fNN l1Vls  
V U3RFl  
4. selectin 2BccE  
d4y#n=HnnV  
5. anti-idiotypic antibody (¦ÁId) *i"9D:  
r)<A YX]J  
6. major histocompatibility complex(MHC) J=A)]YE  
*byUqY3(  
7. immunotolerance \Ec<ch[)c  
EX)&|2w  
8. biological reponse modifier(BRM) ,%pCcM)  
r-qe7K@p  
9. immune reponse gene (Ir gene) eMGJx"a  
pGie!2T E  
10. reshaped antibody (or reconstituted antibody) @IG's-  
TQR5V\{&%  
¶þ. ¼ò´ðÌ⣨ÿÌâ8·Ö£¬¹²32·Ö£© 4Kj.o  
}Rh\JDiQ  
1. ¼òÊö°×ϸ°û½éËØ6(IL-6)Ö÷ÒªµÄÉúÎïѧ»îÐÔ¡£ D]~K-[V?l  
<H-Nft>O  
2. ϸ°û¶¾ÐÔTÁܰÍϸ°û(Tc»òCTL)Ó뿹ÌåÒÀÀµµÄϸ°û½éµ¼µÄϸ°û¶¾(ADCC)ɱÉË»úÀíÓкβ»Í¬? yZlT#^$\  
oidZWy  
3. ¼òÊöµÚ¢ôÐÍ(³Ù·¢ÐÍ)±ä̬·´Ó¦µÄ·¢Éú»úÀí¡£ y 4i3m(S  
LL<xygd  
4. NKϸ°ûÓÐÄÄЩÖ÷ÒªµÄ±íÃæ±ê¼Ç?NKϸ°ûÓÐÄÄЩÖ÷ÒªµÄÉúÎïѧ»îÐÔ? x?AG*' h&  
~&Z>fgOTJ  
Èý. ÎÊ´ðÌâ(ÿÌâ14·Ö,¹²28·Ö) ¹©´«È¾²¡Ñ§×¨ÒµÊÔÌ⣺  'z} t= ?  
66val"^W  
1. »úÌåÓÐÄÄЩÃâÒßϸ°ûºÍÃâÒß·Ö×Ó²ÎÓ뿹²¡¶¾¸ÐȾ?ËüÃÇÊÇÈçºÎ·¢»Ó²¡¶¾ÃâÒß×÷ÓõÄ? EL,k z8  
3?o4  
2. Ŀǰµ¥¿Ë¡¿¹ÌåÔÚ²¡¶¾Ñ§ÖÐÓÐÄÄЩÖ÷ÒªÓÃ;?½ñºó¿ÉÄÜÓÐÄÄЩÖ÷ÒªµÄ·¢Õ¹·½Ïò? ¡¡ <+QdBp'd;  
ZSf &M  
¹©Ïû»¯ÄÚ¿Æ×¨ÒµÊÔÌ⣺ TFXBN.?9T  
7I3_$uF  
1. ĿǰÌåÄÚºÍÌåÍâ¼ì²âÖ×Áö»¼ÕßÃâÒß¹¦Äܵķ½·¨Ö÷ÒªÓÐÄÄЩ?·Ö±ðÐðÊöÿÖÖ·½·¨µÄÔ­ÀíºÍ½á¹û²â¶¨? 4  OPY  
'#6e Ub  
2. Ŀǰµ¥¿Ë¡¿¹ÌåÔÚÖ×ÁöѧÖÐÓÐÄÄЩÖ÷ÒªµÄÓÃ;?½ñºó¿ÉÄÜÓÐÄÄЩÖ÷ÒªµÄ·¢Õ¹·½Ïò? ¡¡ r;Sk[Y5#  
OnTe_JML  
µÚËľüÒ½´óѧһ¾Å¾ÅËÄÄê¹¥¶Á²©Ê¿Ñ§Î»Èëѧ¿¼ÊÔÊÔÌâ ѧ¿Æ×¨Òµ: ]\*^G@HA2  
oSCaP,P  
´«È¾²¡Ñ§¡¢ Ïû»¯ÄÚ¿Æ ¿¼ÊÔ¿ÆÄ¿: U[wx){[|  
kj6:P$tH  
ÃâÒßѧ UA<Fxt  
--$* q"  
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© J&8KIOz14Z  
=x<N+vjXY  
1. CD8 j [U#J  
Gxw1P@<F:  
2. T cell receptor ¦Á and ¦Â chain (TCR¦Á¦Â ) XPdmz!,b  
f~VlCdf+  
3. immunoglobulin fold(Ig fold) Znb={hh  
>jt2vU@t.  
4. cadherin (Ca-dependent cell adhesion moleculers) x;~:p;]J2F  
/DAR'9@h  
5. idiotype-anti-idiotypic antibody immune network theory &jJu=6 U B  
?X@!jB,Pv  
6. HLA class II antigen {s8c@-'  
v~mVf.j1  
7. complementarity-determining region (CDR) *2h%dT:,%  
? Bf>G]zx  
8. perforin(or pore-forming protein ,PFP) -Q20af-  
_,drOF|e  
9. high affinity IL-2 receptor gGrVpOzBj  
@f-:C+(Nsg  
10. artificial active immunization _ $a3lR  
3-/|G-4k7  
¶þ. ¼ò´ðÌ⣨ÿÌâ8·Ö£¬¹²32·Ö£© Da-Lf2qT9  
A|ZT ;\  
1. ¼òÊö°×ϸ°û½éËØ2(IL-2)Ö÷ÒªµÄÉúÎïѧ»îÐÔ¼°ÆäÔÚÁÙ´²ÖÎÁÆÖеÄÓ¦Óᣠ` @QZK0Ox  
M`Q$-#E:  
2. Çë±È½ÏµÚ¢ñÐÍ(ËÙ·¢ÐÍ)³¬Ãô·´Ó¦ÓëµÚ¢ôÐÍ(³Ù·¢ÐÍ)³¬Ãô·´Ó¦µÄ·¢²¡Ìص㡣 BA h'H&;V  
Ja6KO2}p  
3. ÊÔÊö·ÖÃÚÐÍIgA(secretory IgA)µÄ½á¹¹ÌصãºÍºÏ³É·ÖÃÚ¹ý³Ì¡£ ?oYO !  
5_(\Cd<#  
4. ÊԱȽÏT¡¢BÁܰÍϸ°ûϸ°ûĤ±íÃæ·Ö×Ó(Èç±íÃæ¿¹Ô­¡¢±íÃæÊÜÌåµÈ)µÄÒìͬµã¡£ CV0id&Nv  
Y D<3#Dr]  
Èý. ÎÊ´ðÌâ(ÿÌâ14·Ö,¹²28·Ö¡£Çë×¢Ò⣺ÿλ¿¼ÉúÖ»ÄÜ´Ó1¡¢2ÌâÖÐѡһÌâ,3¡¢4ÌâÖÐѡһÌâ,¹²´ðÁ½Ìâ,¶à´ðÕß²»¼Æ·Ö¡£) 1. Ŀǰ¼ì²âϸ°ûÒò×ÓÖ÷ÒªÓÐÉúÎïѧ»îÐÔ¼ì²â·¨ºÍÃâÒßѧ¼ì²â·¨,Çë¾ÙÀý·Ö±ðÐðÊöÁ½ÖÖ·½·¨µÄʵÑéÔ­Àí¡£ a&'9[9E1  
]^ R':YE  
2. ΪÁ˱ÜÃâIgG¿¹ÌåFc¶Î·ÇÌØÒìÐÔ×÷ÓÃ,³£Ó¦ÓÃθµ°°×øˮ½âµÄF(ab¡¯)2¶Î,ÊÔÎÊÈçºÎÓ¦ÓÃSDS-PAGE·½·¨¶ÔF(ab¡¯)2½øÐмø¶¨? y-hTTd"{  
 I0 mp[6  
3. ÊÔÊö¿¹Ö×Áö»ùÒò¹¤³Ì¿¹ÌåµÄÑо¿½øÕ¹¡£ it}h8:^<  
GlJ[rD  
4. ÊÔÊö¿¹²¡¶¾»ùÒò¹¤³Ì¿¹ÌåµÄÑо¿½øÕ¹¡£ ¡¡ }2]|*?1,  
T1C_L? L  
µÚËľüÒ½´óѧһ¾Å¾ÅÎåÄê¹¥¶Á²©Ê¿Ñ§Î»Èëѧ¿¼ÊÔÊÔÌâ M86"J:\u]  
.?u<|4jE6  
ѧ¿Æ×¨Òµ£ºÃâÒßѧ¡¢´«È¾²¡Ñ§¡¢Ïû»¯ÄÚ¿Æ ¿¼ÊÔ¿ÆÄ¿£ºÃâÒßѧ {.LJ(|(Mz  
d`/8Q9tQ  
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© :A8r{`R'N  
|" }rdOV)  
1. immunoglobulin gene rearrangement /bykIUTKI  
+<Gp >c  
2. the common chain of cytokine receptor (or a cytokine receptor subunit shared by some cytokine receptors) <{W{ Y\_A>  
Z#}sK5s  
3. flow cytometry(FCM) i "V.$|,  
S})f`X9_}  
4. carrier effect $6n J+  
J?V$V >d  
5. positive selection of T lymphocytes in thymus !/,oQoG  
pEwo}NS*H  
6. mouse TH1(Th1) and TH2(Th2) subsets |pHlBzHj  
-1 dD~S$  
7. perforin (pore-forming protein ,PFP) Zv}F?4T~:  
H|aFs.SEQ  
8. ADCC(antibody-dependent cell-mediated cytotoxicity) -;gQy[U  
LZ)g&A(j?  
9. SH-2(src-homology region 2) t0f7dU3e;L  
n>)aw4  
10. Ab2¦Â (internal image) :? )!yI  
i1x4$}  
¶þ. ¼ò´ðÌ⣨ÿÌâ8·Ö£¬¹²32·Ö£© ,<Cl^ ^a,  
N&G'i.w/  
1. ½üÄêÀ´ÔÚÈËÀà°×ϸ°û·Ö»¯¿¹Ô­(CD)Ñо¿ÁìÓòÖÐÓÐÄÄЩÖ÷Òª½øÕ¹? 3!9JXq%Hl  
Ar\fA)UQ`  
2. ²ÎÓë»î»¯Tϸ°ûÓë»î»¯Bϸ°ûÏ໥×÷ÓõķÖ×ÓÖ÷ÒªÓÐÄÄЩ?¼òÊöÆä½á¹¹ºÍ¹¦ÄÜ? +7%?p"gEY\  
fK:4jl-r  
3. ÊÔÊöHLAÔÚÁÙ´²ÉϵÄÖ÷ÒªÓ¦ÓᣠHx6O Dj[-  
r ??_2>Q  
4. Àý¾ÙÈýÖÖ´ÓÈËÍâÖÜѪµ¥¸öºËϸ°û(PBMC)Öд¿»¯Tϸ°ûµÄ·½·¨,·Ö±ðÐðÊöÆäʵÑéÔ­ÀíºÍÖ÷Òª²Ù×÷²½Öè¡£ >h%>s4W  
q+[ )i6!?  
5. ÆÀ¼Ûºìϸ°ûÉú³ÉËØ(EPO)¡¢¸ÉÈÅËØ(IFN)ºÍ¼¯Âä´Ì¼¤Òò×Ó(CSF)ÔÚÁÙ´²Ä³Ð©¼²²¡µÄÓ¦Óᣠg5#LoGc  
u)h {"pP  
Èý. Ñ¡ÔñÎÊ´ðÌâ(ÿÌâ10·Ö,¹²20·Ö¡£Çë°´±¨¿¼×¨Òµ´ðÌâ,Èç´ð·Ç±¾×¨ÒµÌâ»ò¶à´ðÌâ¾ùÊÓΪÎÞЧ¡£) _v#pu Fy  
@"s<0T^H  
ÃâÒßѧרҵ£º 7Wef[N\x  
~ ?nn(Q-  
1. ÊÔÊöϸ°ûÒò×ÓÊÜÌåÖÐ,Ig³¬¼Ò×å¡¢ÔìѪÒò×ÓÊÜÌ峬¼Ò×å¡¢Éñ¾­Éú³¤Òò×ÓÊÜÌ峬¼Ò×åÒÔ¼°Ç÷»¯Òò×ÓÊÜÌ峬¼Ò×åµÄÖ÷Òª½á¹¹Ìصã,ÿ¸ö³¬¼Ò×åÀý¾Ù³ö2¸ö³ÉÔ±¡£ =xkaF)AW&v  
&M5v EPR  
2. ÊԱȽÏÈËT¡¢BÁܰÍϸ°ûϸ°ûĤ±íÃæ·Ö×Ó(±íÃæ±ê¼Ç)µÄÒìͬµã,ËüÃÇ·Ö±ð²ÎÓëÄÄЩÖ÷ÒªµÄÃâÒß¹¦ÄÜ? 9Avj\G  
]?_~QE`  
´«È¾²¡Ñ§×¨Òµ£º >A{e ,&  
Ru d9l.n  
1. ÈËÀàÃâÒßȱÏݲ¡¶¾(HIV)¸ÐȾÈËÌåºó,ÃâÒß¹¦Äܿɷ¢ÉúÄÄЩÖ÷ÒªµÄ±ä»¯?»úÀíÊÇʲô?ÈçºÎ½øÐÐÏàÓ¦µÄÃâÒßѧ¹¦Äܼì²â£¿ E[t[R<v,P!  
>]_6|Wfl  
2. ÇëÆÀÊöÉö×ÛºÏÕ÷³öѪÈȲ¡¶¾(HFRSV)¸ÐȾºó»úÌåÃâÒßѧ±ä»¯µÄÓ벡ÀíËðÉ˵ĹØÏµ¡£ o.Ww .F  
j+'ua=T3  
Ïû»¯×¨Òµ£º F ]X<q uuL  
#:=c)[G8  
1.ÊÔÊöÓëÏû»¯ÏµÍ³ÓйصÄÖ×ÁöÏà¹Ø¿¹Ô­Ñо¿µÄ½øÕ¹¡£ +D @B eQu  
EyR/   
2.¼òÊöճĤÏà¹ØÁܰÍÑù×éÖ¯(mucosal assiociated lymphoid tissue,MALT)µÄ×é³ÉºÍ¹¦ÄÜÌØµã¡£·ÖÃÚÐÍIgAÊÇÈçºÎ½øÐкϳɺͷÖÃÚµÄ? 6{d?3Jk  
W`LG.`JW  
µÚËľüÒ½´óѧһ¾Å¾ÅÁùÄê¹¥¶Á²©Ê¿Ñ§Î»Èëѧ¿¼ÊÔÊÔÌâ ÃâÒßѧÊÔÌâ :BR_%$  
=M:Po0?0E  
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© ?v,c)  
QpzdlB44l  
1. Fas(CD95)/FasL A/9<} m  
Msvs98LvW  
2. common chain of cytokine receptor i+QVs_jW  
f }r \  
3 . TCR/CD3 complex M'|[:I.V  
g#fn(A  
4. negaive selection of thymocytes )M.g<[= ^  
Tn,_0  
5. artificial active immune ,;YNI  
<% mD#S  
6. anti-idiotypic QgH{J8 0  
^Rl?)_)1HE  
7. IgSF  0zr%8Q(Q  
A'}!'1  
8. Integrin 3 P75: v  
D\ZH1C!d  
9. chemokine z+M{z r  
~U7Bo(EJp  
10. B7/CD28 +MYrNR.p  
cJ?,\@uuP  
¶þ. ÎÊ´ðÌ⣨ÿÌâ12·Ö£¬¹²60·Ö£© ( + S-  
,6^Xn=o #  
1. ±È½ÏMHC¢ñºÍMHC¢òÀ࿹ԭ²ÎÓëµÄ¼Ó¹¤Ìá³Ê¿¹Ô­µÄ¹ý³Ì¡£ X% 99@qv  
*E>R1bJ8  
2. ±È½ÏCTLºÍNKɱÉ˰Ðϸ°ûʱʶ±ðºÍɱÉË»úÖÆµÄÌØµã¡£ P1L+Vnfu  
?|oN}y"i  
3. ±È½ÏÃâÒßѧ¼ì²â·¨ºÍÉúÎïѧ»îÐÔ¼ì²â·¨¼ì²âϸ°ûÒò×ÓµÄÓÅȱµã¡£ 8t< X  
npytb*[|c  
4. ·¢ÏÖÒ»ÖÖеİ×ϸ°û·Ö»¯¿¹Ô­»òÖ×ÁöÏà¹Ø¿¹Ô­,²¢ÖƱ¸Á˵¥¿Ë¡¿¹Ìå,ÊÔÉè¼ÆÊµÑé·½°¸¿Ë¡´Ë»ùÒò¡£ &&jQ4@m}j  
1Xh@x  
5. Ñ¡ÔñÏÂÊöÖÐÒ»¸öרÌâ,ÐðÊöÎÒ¹úÔÚÕâÒ»Ñо¿ÁìÓòµÄÏÖ×´¼°ÃæÁÙµÄÌôÕ½1)Ö×ÁöÃâÒߣ»(2)»ùÒòÖÎÁÆ£»(3)CD¿¹Ô­¡£ %#EzZD  
6o]{< T/'  
µÚËľüÒ½´óѧһ¾Å¾ÅÆßÄ격ʿÑо¿ÉúÈëѧ¿¼ÊÔÃâÒßѧÊÔÌâ '9qyf<MlY  
8.%wnH  
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© uARkf'  
SY.koW  
1. B7/CD28 B4zuWCE@  
4y4r;[@U  
2. Th1 subset Mc8_D,7  
Mj2Dat`p9  
3. seven predicated transmembrane domain receptor superfamily£¨STR superfamily£© T1?9E{bC8A  
xVI"sBUu  
4. antibody affinity maturation _BgWy#  
^%6f%]_  
5. AP-1 sVnq|[ /  
c/F!cW{z^  
6. single chain variable fragment£¨ScFv£© |Ul4n@+2  
B 'O1dRj&6  
7. NK cell receptor #K`[XA  
cdI"=B+C\  
8. Zinkernagel-Doherty phenomenon t82*rC IB{  
9Ns%<FRO@  
9. Ig fold _S* QIbO  
+,T}x+D  
10. CD40/CD40L tp ky  
={p<|8`"  
¶þ. ÎÊ´ðÌ⣨ÿÌâ12·Ö£¬¹²36·Ö£© n"~K",~P  
\f]w'qiW5  
1. ÊÔÊöÐØÏÙ΢»·¾³¶ÔÐØÏÙϸ°ûµÄÑ¡Ôñ×÷Óü°ÆäÓëTϸ°û¹¦ÄÜÐÔÑÇȺÐγɵĹØÏµ¡£ ) 5x$J01S  
iP9Dr<P  
2. ÊÔÊöÌåÒºÃâÒßÓ¦´ðµÄ¹æÂÉ£¬»ØÒä·´Ó¦ºÍ¿¹ÌåÀà±ðת»»µÄ»úÖÆÊÇʲô£¿ e-xT.RnQ  
@P=n{-pIW  
3. ÊԴӽṹºÍ¹¦ÄܵȽǶȣ¬²ûÊö°×ϸ°û·Ö»¯¿¹Ô­£¨CD£©¡¢Õ³¸½·Ö×Ó£¨integrin£©ºÍÃâÒßÇòµ°°×³¬¼Ò×壨IgSF£©ÈýÀà·Ö×ÓµÄÏ໥¹ØÏµ¡£Ä¿Ç°ÔÚÕâÒ»ÁìÓòÖÐÖ÷ÒªÑо¿ÈȵãÊÇʲô£¿ ,W]}mqV%.'  
0N6 X;M{zh  
Èý. ÎÊ´ðÌ⣨24·Ö£¬µÚ1ÌâΪÃâÒßѧרҵ¿¼ÉúÊÔÌ⣬µÚ2ÌâΪѪҺ²¡Ñ§¿Æ¿¼ÉúÊÔÌ⣬µÚ3ÌâΪÏû»¯ÄÚ¿Æ¿¼ÉúÊÔÌ⣬ֻÔÊÐí´ð±¾×¨ÒµÊÔÌ⣩ HuxvIg  
^R+CkF4l l  
1. ÊԱȽÏTCRºÍBCR½á¹¹¼°Æäʶ±ð¿¹Ô­¡¢ÁܰÍϸ°û»î»¯ÐźŵķÖ×Ó»úÀí¡££¨ÃâÒßѧרҵ£©¡£ `"xzC $  
OaByfo<S  
2. ÊÔÊö°×Ѫ²¡ÃâÒßѧ·ÖÐÍÀíÂۺͷ½·¨µÄÑо¿½øÕ¹¡££¨ÑªÒº²¡Ñ§×¨Òµ£©¡£ ~ihi!u%~}  
V Kc`mE  
3. ÊÔÊöÖ×ÁöÒßÃçµÄÑо¿½øÕ¹¡££¨Ïû»¯ÄÚ¿Æ×¨Òµ£©¡£ <rU+{&FKNL  
20 Rm|CNH?  
Ò»¾Å¾Å°ËÄ격ʿÑо¿ÉúÈëѧ¿¼ÊÔÊÔÌâ £¨ÃâÒßѧרҵºÍרҵ»ù´¡£© )1)&fN41i#  
sBE@{w%  
Ò».Ãû´Ê½âÊÍ£¨Ã¿Ìâ3·Ö£¬¹²45·Ö£© On+0@hh  
9q^7%b,  
1.Co-stimulators (or co-stimulating molecules) "x3!F&  
Lf Y[Z4  
2.NK-kB 2T"[$iH!7  
*m 6*sIR  
3.Immunoglobulin superfamily ;tZ8Sh)  
gdqED}v  
4.antigen-presenting cell (APC) 9H%ixBnM  
*MN("<A_  
5.death domain 1| xKb (_l  
w`Rt"d_B  
6.CCR and CXCR ,0 n=*o@W  
g^k=z:n3,  
7.Lectin (or mitogen) * \ tR  
:-b-)*TC;  
8.Clusters of differentiation, CD) .zdmUS :  
\j vS`+  
9.B7 family S ^@# %>  
u$1^=  
10.Cytotoxic T lymphocyte, CTL) l @r`NFWD@  
'/F~vSQsR  
11.IL-15 and IL-15 receptor (IL-15R) %U& ztvR0C  
&_Gu'A({J  
12.MHC restriction ~#JX 0J=  
R!_1*H$  
13.Affinity-chromatography `b[@GGv  
<V4"+5cJ8  
14.Cyctosprin A, CsA vP/sG5$x  
8X= 2# &)  
15.Antibody-dependent cell-mediated cytotoxicity, ADCC) (FNX>2Mv  
~fly6j|u  
¶þ.ÎÊ´ðÌ⣨ÿÌâ10·Ö£¬¹²30·Ö£© S >\\n^SbT  
@|Hx >|p  
1.ºÎΪTh1ºÍ Th2ÑÇȺ£¿ÈçºÎ¼ì²â£¿ÔÚÁÙ´²ÉÏÓкÎÒâÒ壿 .+CMm5T  
2rX}A3%9^^  
2.ÊÔÊöÃâÒßÇòµ°°×£¨Ig£©µÄ½á¹¹Ó빦ÄܵĹØÏµ¡£ 8B7,qxZ  
)yv~wi  
3.ÊԱȽÏTϸ°ûÊÜÌ壨TCR/CD3£©ÓëBϸ°ûÊÜÌ壨BCR£©µÄ×é³É¡¢½á¹¹¼°Æäʶ±ð ¿¹Ô­µÄÌØµã¡£ o(Ro/U(Wu  
aW$))J)0  
Èý.Ñ¡ÔñÎÊ´ðÌ⣨¸÷רҵ¿¼ÉúÖ»´ðÒ»µÀ±¾×¨ÒµÊÔÌ⣬25·Ö£© \!'K#%]9  
&Zm1(k6&K  
ÃâÒßѧרҵ£º 3a6  
vTYgWR ,h  
1.ÊÔÊöB7/CD28, CTLA-4£¬CD40/CD40L£¬LFA-1/ICAM-1£¬CD2/LFA-3µÄ½á¹¹¡¢·Ö²¼ÒÔ¼°Ï໥×÷Óúó½éµ¼µÄÖ÷ÒªÉúÎïѧ¹¦ÄÜ¡£ 29h_oNO  
gd\b]L?>O  
Ïû»¯ÄÚ¿Æ£º 2.Ö×Áö¿¹Ô­·ÖΪÄļ¸Àࣿ»úÌ忹Ö×ÁöÃâÒßÖ÷ÒªÓÐÄÄЩÒòËØ£¨»úÖÆ£©£¿¼òÊöÌá¸ß¿¹Ö×ÁöÃâÒßÑо¿µÄÂԲߡ£ +8V |  
/pnQKy.  
ѪҺ²¡Ñ§×¨Òµ£º 3.ºÎΪ°×Ѫ²¡µÄÃâÒßѧ·ÖÐÍ£¿ºÎÎªÒÆÖ²ÎËÞÖ÷·´Ó¦£*****VHR£©£¿GVHR·¢ÉúµÄÖ÷ÒªÔ­Òò£¨Ìõ¼þ£©ÊÇʲô£¿ |0a GX]Y  
`v$Bib)  
Ò»¾Å¾ÅÄê¾Å²©Ê¿ÉúÈëѧ¿¼ÊÔÊÔÌâ (רҵ»ù´¡: ÃâÒßѧ) OL$^7F B  
=J&aN1Hgt  
Ò».Ãû´Ê½âÊÍ(ÿÌâ5·Ö,¹²45·Ö) Jl^THoEL  
&5;y&dh  
1. ADCC(antibody dependent cell-mediated cytotoxicity) |oJ R+  
6dX l ny1H  
2. »·æß¾úËØ(cyclosporin) DYvg^b  
]%/a '[  
3. KIR(killer cell inhibitory receptor) xDBHnr}[  
)v?-[ oR  
4. HLDA(human leucocyte differentiation antigen) Oe%jV,S|V  
#o-CG PE  
5. Interleukin 18(IL-18) T@H2[ 7[;  
s|=.L&"   
6. ÕûºÏËØ(integrin) C:d$   
1)f~OL8o  
7. Fas/FasL *A d7GG1/u  
C]+T5W\"<B  
8. FcR(ÃâÒßÇòµ°°×Fc¶ÎÊÜÌå) L]HYk}oD.  
Z'sO9Sg8>  
9. ϸ°û¼äÕ³¸½·Ö×Ó(ICAM) 13T0"}  
uua1_# a  
10. Th1/Th2 iy_\1jB0  
(e;9 ,~u)  
11. »ùÒòÒßÃç(DNAÒßÃç) z ~BrKdS  
MO$ dim>  
12. chemokines and chemokine receptor ly] n2RK  
h8!;RN[  
13. ÃâÒßÄÍÊÜ W<D(M.61A  
88ydAx#P  
14. ¹²´Ì¼¤·Ö×Ó H19CVc\B  
:K6(`J3Y"^  
15. ËÀÍö½á¹¹Óò(death domain) =Jx,.|Bf  
X;ZR"YgT  
¶þ.ÎÊ´ðÌâ(µÚ1¡¢2Ìâ¸÷18·Ö,µÚ3Ìâ19·Ö) 1Bz'$u;  
7^J-5lY3S  
1. ÊԱȽÏɱÉËÐÔTϸ°û(CTL)Óë×ÔȻɱÉËϸ°û(NK)ÔÚɱÉ˰Ðϸ°û¹ý³ÌÖÐ,ʶ±ðϸ°û¶¾¼°½éµ¼ÃâÒß¹¦ÄÜÓкβ»Í¬? df7z& {R  
WqC6 c&NM  
2. 70Äê´úÒÔÀ´,ÓйØIgºÍÌåÒºÃâÒßÑо¿´æÔÚÒÔϼ¸ÏîÖØ´ó·¢ÏÖºÍÍ»ÆÆ¶ø»ñµÃҽѧºÍÉúÎïѧŵ±´¶û½±,Çë·Ö±ð²ûÊöËüÃǵÄÀíÂÛÒâÒå¼°ÔÚҽѧʵ¼ùÖеÄÓ¦Óᣠ;mLbJT   
?eb2T`\0Q  
£¨1£©1972Ä꣺θµ°°×øºÍľ¹Ïµ°°×øˮ½âIg£¬»ñµÃFab¡¢Fc¡¢F£¨ab¡¯£©2µÈƬ¶Î G1"=}Wt`  
^J>jU`)CJ  
£¨2£©1977Ä꣺·ÅÉäÃâÒß·¨ kgz2/,   
d*lnXzQor  
£¨3£©1984Ä꣺ÁܰÍϸ°ûÔÓ½»ÁöºÍµ¥¿Ë¡¿¹Ìå 1b'1vp  
8<t?o'9I  
£¨4£©1987Äê: Ig»ùÒòµÄ½á¹¹ 3. ½üÄêÀ´ÔÚÖ×ÁöÃâÒßÑо¿ÁìÓòÖÐÓÐÄÄÐ©ÖØÒª½øÕ¹?ÊÔÊöµ±Ç°Ìá¸ß»úÌ忹Ö×ÁöÃâÒßµÄÖ÷Òª²ßÂÔ¡£ %Ya-;&;`  
Iy](?b  
Ò»¾Å¾Å¾ÅÄ격ʿÉúÈëѧ¿¼ÊÔÊÔÌâ(ÃâÒßѧרҵ) ÎÊ´ðÌâ(ÿÌâ25·Ö) BcT|TX+ct  
NdQXQa?,  
1. ÊԱȽÏTϸ°ûÊÜÌ壨TCR£©¡¢Bϸ°ûÊÜÌ壨BCR£©ºÍNKϸ°ûÊÜÌ壨NKCR£©µÄ×é³É£¬Ê¶±ðÅäÌåÒÔ¼°ÐźÅתµ¼µÄÒìͬµã¡£ 4\?I4|{pC  
PL 8eM]XS  
2. ÒÔÐØÏÙÒÀÀµ¿¹Ô­´Ì¼¤»úÌå²úÉú¿¹ÌåµÄÃâÒßÓ¦´ðΪÀý£¬Tϸ°ûºÍBϸ°ûÊÇÈçºÎÏ໥×÷Óã¿ÓÐÄÄЩճ¸½·Ö×Ӻ͹²´Ì¼¤·Ö×Ó²ÎÓëT¡¢Bϸ°ûµÄÏ໥×÷Óã¿ %xR;8IO  
u+zq:2)H6  
3. Éö×ÛºÏÕ÷³öѪÈÈ(HFRS)²¡¶¾µÄ½á¹¹»ùÒòÒѾ­¸ãÇå³þ,ΪÁË֤ʵHFRS²¡¶¾¸ÐȾ»úÌå(ÒÔBalb/CСÊóΪÀý)¿É²úÉúHFRS²¡¶¾ºËÒ¿ǵ°°×(NP)ÌØÒìÐÔCTL,²¢ÔÚÃâÒß·À»¤ÖÐÆðÖØÒª×÷ÓÃ,ÇëÓ¦ÓÃÃâÒßѧÀíÂۺͷ½·¨,Éè¼ÆÒ»ÏµÍ³ÊµÑé,¼ÓÒÔ֤ʵ¡£ 4. Àý¾Ù¶þ¸ö½üÄêÀ´Ï¸°ûºÍ·Ö×ÓÃâÒßѧÑо¿ÖгöÏÖµÄеÄÈȵã,Çë·Ö±ðÆÀÊöÆäÑо¿ÒâÒå¡¢·¢Õ¹Ç÷ÊÆÒÔ¼°Ó¦ÓÃǰ¾°¡£
ÆÀ¼ÛÒ»ÏÂÄãä¯ÀÀ´ËÌû×ӵĸÐÊÜ

¾«²Ê

¸Ð¶¯

¸ãЦ

¿ªÐÄ

·ßÅ­

ÎÞÁÄ

¹àË®

  
ÃèÊö
¿ìËٻظ´

ÑéÖ¤ÎÊÌâ:
freekaobo¹Ù·½Î¢ÐŶ©ÔĺŠÕýÈ·´ð°¸:¿¼²©
°´"Ctrl+Enter"Ö±½ÓÌá½»